- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Michael Chiang: How the National Eye Institute Is Building Confidence in Ophthalmology Biosimilars
Michael Chiang, MD, director of the National Eye Institute, discusses how his team is working to instill greater confidence in ophthalmology biosimilars among wary ophthalmologists.
Finding the right people to research ophthalmology biosimilars will be critical for the National Eye Institute (NEI) to help address hesitency and mistrust in these products among ophthalmologists, said Michael Chiang, MD, director of the NEI.
Transcript
What is the NEI approach to newly emerging ophthalmology biosimilars, especially as we begin to see hesitancy among retinal specialists to use biosimilars despite potential cost savings?
Chiang: This is an important question. At the National Eye Institute, our role is, basically, to identify important research studies and to support them. And hopefully, these are going to be the things that lead to advances in clinical care. With biosimilars, some of the fundamental questions are, of course, are they safe? Are they clinically effective? And are they cost-effective? And those are not exactly the same questio, and you don't study them the same way.
So, what I see as our role is, basically, we have to work with people in the community who want to study these questions, identify exactly how we're going to do them, and get the data to really answer the questions that ophthalmologists need.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
